HANDBOOK OF HEMATOLOGIC MALIGNANCIES. 2ND EDITION

• PART I: INTRODUCTION AND OVERVIEW
Chapter 1. Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses
Chapter 2. Familial/Inherited Mutations and Risks of Hematologic Malignancies
Chapter 3. Hematopathology Diagnostic Techniques and Assays
Chapter 4. Minimal Residual Disease Assays
• PART II: MYELOPROLIFERATIVE NEOPLASMS
Chapter 5. Polycythemia Vera
Chapter 6. Essential Thrombocythemia
Chapter 7. Primary Myelofibrosis
Chapter 8. Chronic Myelogenous Leukemia
Chapter 9. Chronic Neutrophilic Leukemia
Chapter 10. Systemic Mastocytosis
Chapter 11. PDGFRA/PDGFRB/FGFR1 Myeloid Neoplasms
• PART III: MYELODYSPLASTIC AND BONE MARROW FAILURE SYNDROMES
Chapter 12. Myelodysplastic Syndromes
Chapter 13. Aplastic Anemia
Chapter 14. Paroxysmal Nocturnal Hemoglobinuria
• PART IV: MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS
Chapter 15. Myelodysplastic/Myeloproliferative Overlap Syndromes
Chapter 16. Chronic Myelomonocytic Leukemia
• PART V: ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES
Chapter 17. Acute Myeloid Leukemia
Chapter 18. Secondary AML and AML With Myelodysplasia-Related Changes
Chapter 19. Acute Promyelocytic Leukemia
Chapter 20. Blastic Plasmacytoid Dendritic Cell Neoplasm
• PART VI: ACUTE LYMPHOID LEUKEMIA
Chapter 21. B-Lymphoblastic Leukemia/Lymphoma
Chapter 22. BCR-ABL1 B-Lymphoblastic Leukemia
Chapter 23. T-Lymphoblastic Lymphoma/Leukemia
• PART VII: ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Chapter 24. Acute Leukemia of Ambiguous Lineage
• PART VIII: MATURE T- AND NK-CELL LEUKEMIA
Chapter 25. T-Cell Prolymphocytic Leukemia
Chapter 26. T-Cell Large Granular Lymphocytic Leukemia
Chapter 27. Aggressive Natural Killer Cell Leukemia
• PART IX: PLASMA CELL DISORDERS
Chapter 28. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas
Chapter 29. Multiple Myeloma
Chapter 30. Waldenström's Macroglobulinemia
Chapter 31. Immunoglobulin Light Chain Amyloidosis
• PART X: HODGKIN LYMPHOMA
Chapter 32. Hodgkin Lymphoma
• PART XI: NON-HODGKIN LYMPHOMA
Chapter 33. Non-Hodgkin Lymphoma Classification and Diagnostic Evaluation
• PART XII: MATURE B-CELL LYMPHOMA
VERY AGGRESSIVE
Chapter 34. Burkitt Lymphoma
AGGRESSIVE
Chapter 35. Diffuse Large B-Cell Lymphoma
Chapter 36. Double Hit Lymphoma
Chapter 37. Mantle Cell Lymphoma
Chapter 38. Primary Mediastinal Large B-Cell Lymphoma
Chapter 39. Primary Central Nervous System Lymphoma
Chapter 40. HIV-Related Lymphomas
INDOLENT
Chapter 41. Follicular Lymphoma
Chapter 42. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chapter 43. Hairy Cell Leukemia
Chapter 44. Marginal Zone Lymphoma
Chapter 45. Mucosa-Associated Lymphoid Tissue Lymphoma
• PART XIII: MATURE T/NK-CELL LYMPHOMA
Chapter 46. Adult T-Cell Leukemia/Lymphoma
Chapter 47. Anaplastic Large Cell Lymphoma, ALK Positive
Chapter 48. Extranodal Natural Killer/T-Cell Lymphoma
Chapter 49. Mycosis Fungoides
Chapter 50. Hepatosplenic T-Cell Lymphoma
• PART XIV: HISTIOCYTIC/DENDRITIC CELL NEOPLASMS
Chapter 51. Histiocytic Sarcoma, Langerhans Cell Histiocytosis, Erdheim-Chester Disease, and Rosai-Dorfman Disease
Chapter 52. Hemophagocytic Lymphohistiocytosis
• PART XV: BONE MARROW TRANSPLANTATION
Chapter 53. Autologous Bone Marrow Transplantation
Chapter 54. Allogeneic Bone Marrow Transplantation
• PART XVI: NEW CELLULAR IMMUNOTHERAPY
Chapter 55. CAR-T and Novel Cellular Therapeutic Options in Hematologic Malignancies
Chapter 56. CD19 CAR-T Therapy
Chapter 57. Cytokine Release Syndrome
• PART XVII: EMERGENCIES IN HEMATOLOGY
Chapter 58. Cancer Associated Thrombosis
Chapter 59. Tumor Lysis Syndrome
Chapter 60. Thrombotic Microangiopathy
Chapter 61. Therapeutic Apheresis Indications
• PART XVIII: NEW CLINICAL CASES IN MALIGNANT HEMATOLOGY
Chapter 62. Challenging Case Vignettes with Follow-Up Questions
Appendix: Pathology Supplement

This revised and updated second edition of Handbook of Hematologic Malignancies continues to be an essential and "go-to" resource for the busy hematologist, hematologic oncologist, hematopathologist, oncology advanced practice provider, oncology nurse, and trainee. Concisely organized, each chapter provides the most current, need-to-know points of diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematological malignancy. Chapters are complete with richly illustrated figures to highlight the hematopathologic characteristics of diseases in addition to helpful tables on differential diagnosis, prognostic scoring systems, molecular profiles, and therapeutic options. A new case-based chapter concludes the handbook with clinical cases designed to test a clinician's knowledge of pathologic diagnosis and clinical presentation of diseases covered in the book. With over twenty new FDA-approved indications since publication of the first edition, including breakthroughs with CAR-T therapy, and other evidence-based treatment options for patients with hematologic disease, this book serves as quick reference to practice changing information on challenging diagnostic dilemmas, frontline and refractory treatment scenarios, and more.
The subspecialty field of hematologic oncology is ever-changing and expanding with available treatment options and this second edition keeps the busy clinician abreast of recent findings and their impact on evidence-based treatment and management. Written by experienced clinicians at the world-renowned Moffitt Cancer Center in Tampa, Florida, as well as contributions from leading academicians, hematologists, and oncologists throughout the country, this unique handbook is packed with authoritative knowledge and clinical insight into all known hematologic cancers.

Key Features:
• Includes seven new chapters covering CAR-T and novel therapeutic options including CD19 CAR-T therapy, novel cellular therapies, cytokine release syndrome, cancer associated thrombosis, and more
• Comprises compact and updated disease-site chapters describing new standards of care and management considerations in bullet point format with key references
• Highlights important diagnostic tools that assist with conducting key differential diagnoses and unveiling answers to diagnostic dilemmas
• Provides updates of potential practice-changing clinical trials and paradigm shifting treatment considerations in each disease-based chapter
• Purchase includes digital access for use on most mobile devices or computers